Proactive Investors Interview – Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy for DMT Intellectual Property
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the Company has disclosed that its intellectual property patent applications, filed in early 2021 for AP-188, included novel salt forms of DMT.
Mr. Moreau explains that a novel salt form of a drug is a new and separate structure from the original compound and is considered a new composition of matter. Many drug compounds’ core structures can often be paired with a salt. Different salts can improve the core drug in several ways, including improved efficacy, safety/tolerability, and stability.